ADORA2A and neoplasm: incorporated a small molecule agonist of A2a adenosine receptor, SCH58261, within the NPs that were attached to the CAR‐TCs’ surface to be released in the tumor microenvironment and inhibit the immunosuppressive effect of the adenosine released by the tumor cells on the TCs.[105] They took advantage of crosslinked multilamellar liposomes conjugated to the thiol groups of CAR‐TCs’ surface through their maleimide containing lipids, while the nonreacted maleimide groups were further PEGylated.